Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT-1
- Development stage
- Preclinical
- Lead developer
- Imagine Pharmaceuticals
- Administration
- Oral
01
Overview
PT-1 is an investigational oral biologic being developed by Imagine Pharmaceuticals, currently in preclinical development. It acts as an erythropoietin (EPO) receptor agonist designed to stimulate erythropoiesis, the process of red blood cell production. The drug is primarily targeted for the treatment of anemia associated with chronic renal failure and chemotherapy-induced anemia. By utilizing a proprietary oral delivery platform, PT-1 aims to provide a non-invasive alternative to traditional erythropoiesis-stimulating agents (ESAs) that typically require parenteral administration, potentially improving patient compliance and quality of life.
- Other names
- PT-1 EPOPT1 EPOPT 1 EPO
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on PT-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT-1.